Table 2.

Anti-tumor activity of fruquintinib in multiple xenograft tumor models

Tumor origin	Xenograft model	Dose (mg/kg)	%TGI (% regression)	Significance (t- test, two-tailed vs control)	Body weight change (%)*
Gastric cancer	BGC823 (exp. 1)	0.5	62.3	<0.05	+1.9
		1	74.3	<0.05	+4.9
		2	95.4	<0.01	+3.2
Gastric cancer	BGC-823 (exp. 2)	2	98.6	<0.01	+5.8
		5	106.5(24.1)	<0.01	+6.9
		20	113.3 (48.6)	<0.01	+4.6
Colon cancer	HT-29	0.77	46.4	<0.05	+4.2
		1.92	60.8	<0.01	+3.5
		4.8	80.6	<0.01	+7.4
		12	89.2	<0.01	+7.2
Renal clear cell	Caki-1	0.8	34.0	<0.05	+9.5
carcinoma		2	51.5	<0.01	+6.7
		5	63.2	<0.01	+4.6
Lung cancer	NCI-H460	0.77	40.9	<0.05	+8.1
		1.92	56.9	<0.01	+8.5
		4.8	71.8	<0.01	+6.6
		12	79.3	<0.01	+7.3
Gastric cancer	GAS1T0113	1	44.0	<0.05	−3.6
		Taxotere	46.3	<0.05	−20.9
		1+Taxotere	73.4	<0.01	−21.8
Colon cancer	COL1T0117	1	36.3	<0.05	−0.2
		Oxaliplatin	23.9	>0.05	−12.2
		1+Oxaliplatin	68.1	<0.01	−12.6

^*, body weight change was calculated as (body weight_final / body weight_initial −1) × 100%.